Ilaria Grazia Zizzari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1563548/publications.pdf

Version: 2024-02-01

32 papers	1,160 citations	430874 18 h-index	434195 31 g-index
33 all docs	33 docs citations	33 times ranked	2072 citing authors

#	Article	IF	Citations
1	Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. Clinical Cancer Research, 2022, 28, 1027-1037.	7.0	10
2	Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	3.3	5
3	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2â˜ metastatic breast cancer: Relief from immunosuppression is associated with clinical response. EBioMedicine, 2022, 79, 104010.	6.1	22
4	Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma. International Journal of Molecular Sciences, 2022, 23, 6312.	4.1	6
5	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. Journal of Personalized Medicine, 2021, 11, 651.	2.5	28
6	Antiâ€“PD-1 and Antiâ€“PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 705096.	4.8	47
7	Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. Frontiers in Oncology, 2021, 11, 755433.	2.8	15
8	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-Type Lectin (MGL). Cancers, 2020, 12, 2841.	3.7	10
9	IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. EBioMedicine, 2020, 62, 103098.	6.1	10
10	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. Cancers, 2020, 12, 2620.	3.7	21
11	Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma. Journal of Personalized Medicine, 2020, 10, 112.	2.5	20
12	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. Journal of Personalized Medicine, 2020, 10, 208.	2.5	23
13	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. Frontiers in Immunology, 2020, 11, 1243.	4.8	30
14	Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. Journal of Translational Medicine, 2020, 18, 49.	4.4	114
15	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ¯ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	2.2	8
16	Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?. Cancers, 2019, 11, 1055.	3.7	40
17	Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets. Journal of Clinical Medicine, 2019, 8, 380.	2.4	25
18	A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. Journal of Translational Medicine, 2019, 17, 99.	4.4	52

#	Article	IF	Citations
19	CAR-T cells: the long and winding road to solid tumors. Cell Death and Disease, 2018, 9, 282.	6.3	312
20	TK Inhibitor Pazopanib Primes DCs by Downregulation of the Î²-Catenin Pathway. Cancer Immunology Research, 2018, 6, 711-722.	3.4	47
21	Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells. Frontiers in Immunology, 2018, 9, 2481.	4.8	23
22	Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. BioMed Research International, 2018, 2018, 1-2.	1.9	0
23	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2018, 150, 151-157.	1.4	21
24	Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells. Frontiers in Immunology, 2017, 8, 1179.	4.8	21
25	Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Human Immunology, 2016, 77, 1239-1247.	2.4	8
26	Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 2016, 48, 1369-1378.	3.3	28
27	Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells. Anticancer Research, 2016, 36, 5109-5116.	1.1	11
28	The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions. PLoS ONE, 2015, 10, e0132617.	2.5	35
29	MGL Receptor and Immunity: When the Ligand Can Make the Difference. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	49
30	Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing. Cancer Immunology Research, 2014, 2, 177-186.	3.4	23
31	Targeting of macrophage galactoseâ€type <scp>C</scp>â€type lectin (<scp>MGL</scp>) induces <scp>DC</scp> signaling and activation. European Journal of Immunology, 2012, 42, 936-945.	2.9	84
32	HER2-based recombinant immunogen to target DCs through FcÎ³Rs for cancer immunotherapy. Journal of Molecular Medicine, 2011, 89, 1231-1240.	3.9	12